Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950075 · ClinicalTrials.gov registry record · Phase 2
Study of INBRX-109 in Conventional Chondrosarcoma
A Phase 2 study of Conventional Chondrosarcoma, sponsored by Inhibrx Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT04950075: Active Phase 2 study of Conventional Chondrosarcoma, sponsored by Inhibrx Biosciences.
NCT04950075 is a Phase 2 study of Conventional Chondrosarcoma that is active but no longer recruiting, run by Inhibrx Biosciences. The registered enrollment target is 206 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04950075, a Phase 2 study of Conventional Chondrosarcoma, is active but no longer recruiting, sponsored by Inhibrx Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Primary Outcome
Progression-free survival per RECISTv1.1 will be determined.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INBRX-109
Study Locations (20)
California
- Precision NextGen Oncology & Research Center - Beverly Hills
- University of California, San Francisco (UCSF) - San Francisco
- Sarcoma Oncology Center - Santa Monica
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center - Chicago
- Rush Cancer Center - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Arizona
- Mayo Clinic Cancer Center - Phoenix
Colorado
- University of Colorado - Denver
Connecticut
- Yale Cancer Center - New Haven
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT04950075 still lists
NCT04950075 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Conventional Chondrosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04950075 names 20 study sites across 15 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04950075 about?
NCT04950075 is a clinical study titled "Study of INBRX-109 in Conventional Chondrosarcoma". Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
What is the current status of trial NCT04950075?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2021-09-23. Estimated completion is 2026-12.
What conditions does trial NCT04950075 study?
This clinical trial studies the following conditions: Conventional Chondrosarcoma.
What interventions are being tested in trial NCT04950075?
The interventions under investigation include: Placebo (DRUG), INBRX-109 (DRUG).
Who is sponsoring clinical trial NCT04950075?
This trial is sponsored by Inhibrx Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04950075 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04950075's enrollment target sits among peer trials
206 298th of 2000 higher than 1,703 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI